Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML
NCT07508982 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 52
Last updated 2026-04-03
Summary
This is a phase Ib/II study that aims to investigate the safety, tolerability and explore the efficacy of BCL- XL inhibition in participants with high-risk AML.
Conditions
Interventions
- DRUG
-
Given by IV
- DRUG
-
APG1252
Given by IV
Sponsors & Collaborators
-
M.D. Anderson Cancer Center
lead OTHER
Principal Investigators
-
Tapan Kadia, MD · UT MD Anderson
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-09-01
- Primary Completion
- 2029-12-12
- Completion
- 2031-12-12
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia
NCT05042531 ·Status: UNKNOWN ·Phase: NA
-
Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)
NCT00486265 ·Status: TERMINATED ·Phase: PHASE1
-
Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia
NCT03483948 ·Status: TERMINATED ·Phase: PHASE1
-
Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy
NCT00728520 ·Status: UNKNOWN ·Phase: PHASE2
-
Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients
NCT00952588 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
NCT03072043 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
NCT06389292 ·Status: RECRUITING ·Phase: PHASE3
-
Extension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemia (AML) Patients
NCT06572982 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
NCT01038635 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
NCT01311258 ·Status: RECRUITING
-
Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention.
NCT06754540 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
NCT05404906 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission
NCT00458523 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML
NCT04248595 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
NCT02677922 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)
NCT00926731 ·Status: COMPLETED ·Phase: PHASE1
-
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
NCT04062266 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
NCT01110473 ·Status: COMPLETED ·Phase: PHASE1
-
Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)
NCT00350818 ·Status: COMPLETED ·Phase: PHASE1
-
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
NCT05209152 ·Status: TERMINATED ·Phase: PHASE1
-
Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT02953561 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia
NCT04296214 ·Status: WITHDRAWN
-
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
NCT05175508 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine
NCT03588078 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS
NCT01617226 ·Status: COMPLETED ·Phase: PHASE2